Isis Sees Impressive Phase I Data, HealthSouth’s Downgrade: Healthcare Business Wrap

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Isis Pharmaceuticals (NASDAQ:ISIS) will Phase II trials of its STAT3RX treatment in patients suffering with advanced cancer, following “impressive” preliminary data in a Phase I evaluation. David Hong of the University of Texas says that the early results imply that the “drug can produce responses in patients with advanced cancer who have failed to respond to other therapies.”

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of HealthSouth Corporation (NYSE:HLS) dip subsequent to a downgrade at JMP Securities to Market Perform on valuation earlier Wednesday, pointing to a lack of visibility on medicaid reimbursement.

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) announces a working agreement with BioMarin Pharmaceutical (NASDAQ:BMRN) for the North American rights to Firdapse, which is a treatment of Lambert-Eaton Myasthenic Syndrome. Through the terms, the former will license exclusive rights to Firdapse, while the latter will make a $5 million stake in Catalyst for program advancement.

Don’t Miss: Isis Means Business With This New Treatment.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business